Neoadjuvant therapy for pancreatic neuroendocrine neoplasms: current status and future directions
10.3760/cma.j.cn112139-20250511-00252
- VernacularTitle:胰腺神经内分泌肿瘤新辅助治疗的现状与展望
- Author:
Zhiyao FAN
1
;
Hanxiang ZHAN
1
Author Information
1. 山东大学齐鲁医院普通外科，济南 250012
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Neoadjuvant therapy;
Chemotherapy;
Peptide receptor radionuclide therapy
- From:
Chinese Journal of Surgery
2026;64(1):27-33
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic neuroendocrine neoplasms represent a highly heterogeneous group of malignancies exhibiting a broad spectrum of biological behaviors ranging from indolent to highly aggressive. The formulation of therapeutic strategies requires a comprehensive consideration of patient condition and tumor biological characteristics. Neoadjuvant therapy has demonstrated promising efficacy in tumor downstaging,enhancing R0 resection rates,and improving prognoses across various solid tumors,yet its application in pancreatic neuroendocrine neoplasms remains underexplored with limited clinical evidence. This review systematically examines critical issues in neoadjuvant management of pancreatic neuroendocrine neoplasms based on contemporary guidelines and emerging literature,encompassing patient selection criteria,regimen optimization,response evaluation,and optimal surgical timing. Current challenges persist in standardizing neoadjuvant approaches,necessitating multicenter prospective studies to establish high-level evidence. Future advancements in artificial intelligence and precision medicine hold potential to revolutionize personalized therapeutic paradigms,ultimately improving patient survival outcomes.
